The Economic Burden of Atherosclerotic Cardiovascular Disease in Italy

被引:1
作者
Mennini, Francesco S. [1 ]
Scortichini, Matteo [1 ]
Colivicchi, Furio [2 ]
Maggioni, Aldo P. [3 ]
Sciattella, Paolo [1 ]
机构
[1] Univ Roma Tor Vergata, Fac Econ, Ctr Econ & Int Studies, Econ Evaluat & Hlth Technol Assessment, Via Columbia 2, I-00133 Rome, Italy
[2] San Filippo Neri Hosp, Div Cardiol, Rome, Italy
[3] ANMCO Res Ctr Heart Care Fdn, Florence, Italy
关键词
STATIN THERAPY; EZETIMIBE; RISK; ASSOCIATION; ADHERENCE; EFFICACY;
D O I
10.1007/s40261-024-01365-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundAtherosclerotic cardiovascular diseases remain the primary cause of mortality in Italy. Individuals with a history of acute coronary syndrome, peripheral arterial disease, and ischemic stroke/transient ischemic attack face an elevated risk of recurrent major adverse cardiovascular events, including mortality. The population aging, coupled with increasing risk factors such as diabetes mellitus and obesity, exacerbates the disease's economic impact.ObjectivesThis study aims to comprehensively assess the economic burden of atherosclerotic cardiovascular diseases in Italy, specifically focusing on direct healthcare costs.MethodsWe analyzed real-world data from administrative databases in the Marche region and Local Health Unit Umbria 2. The economic burden of patients discharged with acute coronary syndrome, peripheral arterial disease, and ischemic stroke/transient ischemic attack was evaluated, with a focus on direct costs associated with hospitalizations, drugs, and outpatient visits. Results were stratified by age, sex, comorbidities at baseline, and adherence to lipid-lowering therapy and antihypertensive agents.ResultsAnnually, nearly 350,000 patients were hospitalized for peripheral arterial disease, acute coronary syndrome, or ischemic stroke/transient ischemic attack. Direct health costs averaged <euro>7190 per patient over a 2-year follow-up, with hospitalizations accounting for nearly 70% of the total. Male patients incurred significantly higher costs (<euro>7467) than female patients (<euro>6625). Costs correlated positively with age and with the number of baseline comorbidities, with a range from <euro>5259 (0-1 comorbidities) to <euro>17,095 (4+ comorbidities). Costs were significantly lower in adherent subjects (<euro>6813) compared with non-adherent subjects (<euro>7757).ConclusionsThis study provides valuable insights into the economic implications of atherosclerotic cardiovascular diseases in Italy, emphasizing the necessity of a comprehensive approach to preventive measures, optimal medication adherence, and lifestyle modifications to mitigate its impact.
引用
收藏
页码:739 / 747
页数:9
相关论文
共 50 条
  • [1] The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy
    Case, Brian C.
    Bress, Adam P.
    Kolm, Paul
    Philip, Sephy
    Herrick, Jennifer S.
    Granowitz, Craig B.
    Toth, Peter P.
    Fan, Wenjun
    Wong, Nathan D.
    Hull, Michael
    Weintraub, William S.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (05) : 754 - 761
  • [2] An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease
    Tomlinson, Brian
    Chow, Elaine
    Chan, Paul
    Lam, Christopher Wai Kei
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (12) : 1353 - 1361
  • [3] Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States
    Fonseca, Ana F.
    Byrne, Hannah
    Laguna, Andres
    Itani, Taha
    Studer, Rachel
    Heo, Jihaeng
    Dillon, Allison
    Ferber, Philippe
    Costa-Scharplatz, Madlaina
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (05) : 519 - 529
  • [4] Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease
    Michos, Erin D.
    McEvoy, John W.
    Blumenthal, Roger S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16) : 1557 - 1567
  • [5] Periodontal disease and atherosclerotic cardiovascular disease
    Berent, Robert
    Sinzinger, Helmut
    VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE, 2013, 42 (01) : 3 - 7
  • [6] Economic Burden of Dementia Caused by Cardiovascular Disease in Australia
    Gao, Lan
    Nguyen, Dieu
    Moodie, Marj
    JOURNAL OF ALZHEIMERS DISEASE, 2022, 86 (02) : 601 - 612
  • [7] How to overcome barriers to the implementation of prevention and treatment strategies for atherosclerotic cardiovascular disease through lipid-lowering therapy
    Arca, Marcello
    Averna, Maurizio
    Borghi, Claudio
    Lettino, Maddalena
    Filardi, Pasquale Perrone
    Alberti, Antonia
    Bilato, Claudio
    Calabro, Paolo
    Carubbi, Francesca
    Ciccone, Marco Matteo
    Cipollone, Francesco
    Citroni, Nadia
    De Luca, Leonardo
    Giaccari, Andrea
    Iannuzzo, Gabriella
    Maloberti, Alessandro
    Marcucci, Rossella
    Spinazzola, Pasquale Pignatelli
    Pirro, Matteo
    Pisciotta, Livia
    Sarullo, Filippo
    Sciacqua, Angela
    Suppressa, Patrizia
    Varbella, Ferdinando
    Werba, Jose Pablo
    Zambon, Alberto
    GIORNALE ITALIANO DI CARDIOLOGIA, 2023, 24 (10) : 770 - 780
  • [8] Lipid-lowering therapy for the prevention of atherosclerotic cardiovascular disease: guidelines and clinical practice
    Lucchi, Tiziano
    Cesari, Matteo
    Vergani, Carlo
    GIORNALE ITALIANO DI CARDIOLOGIA, 2020, 21 (04) : 256 - 263
  • [9] Preventative Strategies of Atherosclerotic Cardiovascular Disease
    Prado, Kimberly Buff
    Napierkowski, Daria
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2020, 16 (04): : 253 - 257
  • [10] Primary Prevention of Atherosclerotic Cardiovascular Disease: Controversies and Clinical Considerations
    Newsom, Lydia C.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (04) : 484 - 493